PROphet
®
PROphetNSCLC
TM
Test
PROphet
®
Technology
Resources
For Patients
For Providers
For Pharma
Science
Publications
Presentations
Clinical studies
Collaborators
About Us
News
In the news
Thought Leadership
Press releases
Meetings & Events
Awards
Contact Us
Careers
US openings
Israel openings
Order a test
PROphet
®
PROphetNSCLC
TM
Test
PROphet
®
Technology
Resources
For Patients
For Providers
For Pharma
Science
Publications
Presentations
Clinical Studies
Collaborators
News
In the News
Thought Leadership
Press Releases
Meetings & Events
Awards
Company
About us
Careers
Contact us
Order a test
In the News
Thought Leadership
Press Releases
Meetings & Events
Awards
September 20, 2021
OncoHost Further Assessing Protein Signature for Predicting NSCLC Patients' Immunotherapy Response
Original source
here.
Recent news
June 16, 2025
As AI Dawns in Precision Oncology, 2025 Expected To Be a ‘Turning Point’
Read more
June 6, 2025
OncoHost study offers insights into resistance mechanisms in immunotherapy-treated lung cancer
Read more
June 2, 2025
OncoHost study offers new insights into resistance mechanisms in immunotherapy-treated lung cancer patients
Read more
May 31, 2025
OncoHost Study Offers New Insights into Resistance Mechanisms in Immunotherapy-Treated Lung Cancer Patients
Read more
May 30, 2025
OncoHost Developing NeutroFlow Test for Guiding Cancer Therapy Selection
Read more
May 20, 2025
OncoHost receives a €2.5 million European grant to advance precision oncology
Read more
Read all news
